Scholarlink

<p>Non-small cell lung cancer (NSCLC) is frequently refractory to mitochondrial apoptosis despite oncogenic and therapeutic stress. Although individual anti-apoptotic BCL-2 family members have been implicated in NSCLC survival, it has remained unclear whether this reflects dominant single-protein dependencies or a cooperative pro-survival network. This uncertainty is exacerbated by the high prevalence of p53 mutations, which compromise DNA damage–induced apoptotic signaling. Here, we systematically dissected intrinsic apoptotic dependencies across a panel of human NSCLC cell lines using selective BH3 mimetics targeting BCL-2, BCL-XL or MCL-1. Consistent with previous reports, BH3 mimetics alone provided only limited and heterogeneous sensitization to cisplatin across NSCLC models. Likewise, single-agent inhibition of BCL-2, BCL-XL or MCL-1 elicited weak and variable apoptotic responses. In striking contrast, combined targeting of BCL-XL and MCL-1 was sufficient to trigger rapid, synergistic and irreversible apoptosis in the majority of NSCLC cell lines, even in the absence of genotoxic stress. Commitment to cell death occurred within minutes and was characterized by early mitochondrial outer membrane permeabilization, cytochrome c release and robust effector caspase activation. This apoptotic response strictly required the intrinsic mitochondrial machinery and BAX/BAK function but was entirely independent of p53 status. Apparent resistance to first-generation (WEHI-539) BCL-XL inhibition in a subset of models reflected incomplete target engagement rather than compensatory survival rewiring. Accordingly, apoptosis was fully restored by next-generation BCL-XL inhibition (A-1331852) or by PROTAC-mediated BCL-XL degradation (DT2216). Importantly, platelet-sparing BCL-XL targeting strategies retained strong synergy with MCL-1 inhibition, addressing a key translational limitation of earlier BH3-mimetic approaches. Together, these data redefine apoptotic control in NSCLC as a cooperative restraint imposed by BCL-XL and MCL-1 rather than discrete, context-dependent dependencies, revealing a rapid, p53-independent mitochondrial apoptotic vulnerability with clear therapeutic implications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Liyang Wu,
  • Baris Budak,
  • Oihane Ofogo,
  • Ali Jazaeri Jouneghani,
  • Philippe JeanRichard,
  • Daniel Bachmann,
  • Thomas Kaufmann

摘要

Non-small cell lung cancer (NSCLC) is frequently refractory to mitochondrial apoptosis despite oncogenic and therapeutic stress. Although individual anti-apoptotic BCL-2 family members have been implicated in NSCLC survival, it has remained unclear whether this reflects dominant single-protein dependencies or a cooperative pro-survival network. This uncertainty is exacerbated by the high prevalence of p53 mutations, which compromise DNA damage–induced apoptotic signaling. Here, we systematically dissected intrinsic apoptotic dependencies across a panel of human NSCLC cell lines using selective BH3 mimetics targeting BCL-2, BCL-XL or MCL-1. Consistent with previous reports, BH3 mimetics alone provided only limited and heterogeneous sensitization to cisplatin across NSCLC models. Likewise, single-agent inhibition of BCL-2, BCL-XL or MCL-1 elicited weak and variable apoptotic responses. In striking contrast, combined targeting of BCL-XL and MCL-1 was sufficient to trigger rapid, synergistic and irreversible apoptosis in the majority of NSCLC cell lines, even in the absence of genotoxic stress. Commitment to cell death occurred within minutes and was characterized by early mitochondrial outer membrane permeabilization, cytochrome c release and robust effector caspase activation. This apoptotic response strictly required the intrinsic mitochondrial machinery and BAX/BAK function but was entirely independent of p53 status. Apparent resistance to first-generation (WEHI-539) BCL-XL inhibition in a subset of models reflected incomplete target engagement rather than compensatory survival rewiring. Accordingly, apoptosis was fully restored by next-generation BCL-XL inhibition (A-1331852) or by PROTAC-mediated BCL-XL degradation (DT2216). Importantly, platelet-sparing BCL-XL targeting strategies retained strong synergy with MCL-1 inhibition, addressing a key translational limitation of earlier BH3-mimetic approaches. Together, these data redefine apoptotic control in NSCLC as a cooperative restraint imposed by BCL-XL and MCL-1 rather than discrete, context-dependent dependencies, revealing a rapid, p53-independent mitochondrial apoptotic vulnerability with clear therapeutic implications.